{
  "$schema": "folio-library-entry/v1",
  "id": "10665-340190",
  "blocks": [
    {
      "id": "library/10665-340190/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 7,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "UPDATED RECOMMENDATIONS ON\nHIV PREVENTION, INFANT \nDIAGNOSIS, ANTIRETROVIRAL \nINITIATION AND MONITORING\nGUIDELINES\nMARCH 2021\nUPDATED RECOMMENDATIONS ON\nHIV PREVENTION, INFANT \nDIAGNOSIS, ANTIRETROVIRAL \nINITIATION AND MONITORING\nMARCH 2021\nUpdated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation \nand monitoring: March 2021\nISBN 978-92-4-002223-2 (electronic version)  \nISBN 978-92-4-002224-9 (print version)\n© World Health Organization 2021\nSome rights reserved. This work is available under the Creative Commons Attribution-\nNonCommercial-ShareAlike 3.0 IGO licence",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The title, copyright and licence pages and table of contents of WHO's March 2021 updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring, with ISBNs. The contents list the chapters, annexes, tables and figures, including the PICO questions and technical scoping meetings. It also gives the suggested citation and standard WHO disclaimers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "I. \u0003Abbreviations and acronyms",
      "pageStart": 7,
      "pageEnd": 8,
      "target": "../sections/sec-000-i-abbreviations-and-acronyms.md",
      "narrative": null,
      "content": "AIDS\t\nacquired immunodeficiency syndrome\nART\t\nantiretroviral therapy\nARV\t\nantiretroviral (drug)\nCI\t\nconfidence interval\nCOVID-19\t coronavirus disease\nDALY\t\ndisability-adjusted life-year\nDTG\t\ndolutegravir\nEFV\t\nefavirenz\nGRADE\t\nGrading of Recommendations Assessment, Development and Evaluation\nHIV\t\nhuman immunodeficiency virus\nNNRTI \t\nnon-nucleoside reverse-transcriptase inhibitor\nPI\t\nprotease inhibitor\nPICO\t\npopulation, intervention, comparison and outcome\nPrEP\t\npre-exposure prophylaxis\nTB\t\ntuberculosis\nTDF\t\ntenofovir disoproxil fumarate\nUNAIDS\t\nJoint United Nations Programme on HIV/AIDS",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of abbreviations and acronyms used in the 2021 HIV guideline update.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "II. \u0003Definition of key terms",
      "pageStart": 8,
      "pageEnd": 10,
      "target": "../sections/sec-001-ii-definition-of-key-terms.md",
      "narrative": null,
      "content": "General \nHIV refers to the human immunodeficiency virus. There are two types of HIV: HIV-1 and HIV-2.\nHIV-1 is responsible for the vast majority of HIV infections globally.\nAcute (HIV) infection is the period between a person being infected with HIV and HIV  \nantibodies being detectable by a serological assay.\nAge groups and populations\nThe following definitions for adults, adolescents, children and infants are used in these guidelines \nfor the purpose of implementing recommendations for specific age groups. It is acknowledged  \nthat countries may have other definitions under national laws:\n•",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines key terms used in the 2021 HIV guidelines, starting with HIV types and acute infection. It sets age-group definitions for adults, adolescents, children and infants, and defines key and vulnerable populations. Further definitions cover terms such as serodiscordant couples and partners.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "III. \u0003Acknowledgements",
      "pageStart": 10,
      "pageEnd": 13,
      "target": "../sections/sec-002-iii-acknowledgements.md",
      "narrative": null,
      "content": "WHO gratefully acknowledges the contributions of many individuals and organizations to the \ndevelopment of this guideline.\nGRADE METHODOLOGIST\nNandi Siegfried (independent consultant, South Africa).\nCLINICAL GUIDELINE DEVELOPMENT GROUP\nCo-chairs: Diane Havlir (University of California at San Francisco, USA) and Ilesh Jani \n(Instituto Nacional de Saúde (National Institute of Health), Mozambique).\nElaine Abrams (ICAP at Columbia University, USA), Iryna Andrianova (National HIV \nLaboratory, Ukraine), Moherndran Archary (King Edward VIII Hospital affiliated to the Nelson \nR. Mandela School of Medi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Acknowledges the many contributors to the guideline, starting with the GRADE methodologist and the co-chairs and members of the Clinical Guideline Development Group from many countries. It goes on to name other reviewers, partners and WHO staff. It ends by naming PEPFAR, the US CDC, USAID, Unitaid and the Bill & Melinda Gates Foundation as funders.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "V. \u0003Executive summary",
      "pageStart": 13,
      "pageEnd": 16,
      "target": "../sections/sec-003-v-executive-summary.md",
      "narrative": null,
      "content": "Audience\nThe primary audience for this guideline is national HIV programme managers, people living \nwith HIV, health-care providers and policy-makers in low- and middle-income countries. This \nguideline update will be a useful resource for clinicians and should help to shape the priorities \nof policy-makers in development agencies, international organizations, nongovernmental \norganizations and other implementing partners. This guideline will also be of value to people \nliving with HIV, communities and civil society organizations to ensure they are informed of the \nupdated guidance and to help",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The executive summary identifies the audience as national HIV programme managers, people living with HIV, health-care providers and policy-makers in low- and middle-income countries. It explains that the update followed WHO Guidelines Review Committee procedures and the GRADE approach. It sets out the public health rationale and introduces a summary table of the new recommendations, the revised monitoring algorithm and clinical considerations for rapid ART initiation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "INTRODUCTION",
      "pageStart": 16,
      "pageEnd": 16,
      "target": "../sections/sec-004-1-introduction.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Background and rationale",
      "pageStart": 16,
      "pageEnd": 18,
      "target": "../sections/sec-005-11-background-and-rationale.md",
      "narrative": null,
      "content": "HIV infection is a public health issue. In 2019, more than 38.0 million [31.6 million–44.6 \nmillion] people were living with HIV, and more than 1.7 million [1.2 million–2.2 million] people \nacquired HIV. Nearly 61% of the people newly infected with HIV live in sub-Saharan Africa. \nBetween 2010 and 2019, the epidemic also continued to grow in eastern Europe and central \nAsia, with the number of people acquiring HIV rising by 72%. There were also increases in the \nMiddle East and North Africa (22%) and Latin America (21%) (1). The United Nations General \nAssembly agreed in June 2016 that ending",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the epidemiological background, citing 38 million people living with HIV and 1.7 million new infections in 2019, with rising incidence in eastern Europe, central Asia and other regions. It notes that the 2020 Fast-Track targets were missed despite falling AIDS deaths. It then explains why updated guidance was needed on prevention, infant diagnosis, viral load monitoring and timing of ART for people with TB symptoms.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Objectives",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-006-12-objectives.md",
      "narrative": null,
      "content": "These guidelines are intended to contribute to the 13th WHO Global Programme of Work – \nTriple-Billion initiative – as part of the Global Public Health Goods 1.1.2 as well as the objective \nto meet targets set out in the Sustainable Development Goal 3 to end of AIDS by 2030.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that the guidelines aim to contribute to WHO's 13th General Programme of Work and the goal of ending AIDS by 2030.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Target audience",
      "pageStart": 18,
      "pageEnd": 18,
      "target": "../sections/sec-007-13-target-audience.md",
      "narrative": null,
      "content": "The guidelines are primarily intended for use by national HIV programme managers and policy-\nmakers. They will also be of interest to the following audiences:\n•\tnational HIV treatment and prevention advisory boards;\n•\tnational TB and HIV programme managers;\n•\tmanagers of maternal, newborn and child health programmes;\n•\tmanagers of sexual and reproductive health programmes;\n•\tclinicians and other health service providers;\n•\tmanagers of national laboratory services;\n•\tpeople living with HIV and key population networks and organizations\n•\tcommunity-led and community-based organizations and servic",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the target audience of the guidelines, chiefly national HIV programme managers and policy-makers, as well as clinicians, laboratory managers, community organizations and funding agencies.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Guiding principles",
      "pageStart": 18,
      "pageEnd": 19,
      "target": "../sections/sec-008-14-guiding-principles.md",
      "narrative": null,
      "content": "The following principles have informed the development of these guidelines and should guide \nthe implementation of the recommendations.\n•\tThe guidelines should contribute to and expedite the achievement of key global and national \nHIV goals for 2016–2021 (11), contribute to the new Global Programme of Work – Triple-Billion \ninitiative – as part of the Global Public Health Goods 1.1.2 and to realizing the Sustainable \nDevelopment Goals (12).\n•\tThe guidelines are based on a public health approach to scaling up the use of ARV drugs \nalong the continuum of HIV prevention, treatment and care.\n1 Int",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the guiding principles behind the guidelines, such as a public health approach to scaling up antiretroviral drugs and the involvement of people living with HIV. Others include strengthening wider health systems, protecting human rights and gender equity, and adapting to local context.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Methods for developing the guidelines",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-009-15-methods-for-developing-the-guidelines.md",
      "narrative": null,
      "content": "This publication is linked to the 2016 WHO consolidated guidelines (4) and to previous \nguidelines developed in 2017, 2018 and 2019. These are collectively being compiled into a \nsingle consolidated publication containing all relevant guidance.\nAnnex 1 details the full methods for developing this guideline. In summary, this guideline \nupdate was developed in accordance with procedures established by the WHO Guidelines \nReview Committee (13). The recommendations in the guidelines are based on the GRADE \n(Grading of Recommendations Assessment, Development and Evaluation) approach to \nreviewing e",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarises the methods used to develop the guideline, which links to earlier WHO HIV guidelines and followed Guidelines Review Committee procedures and GRADE. It describes how declarations of interest were managed and how systematic reviews and evidence-to-decision tables informed the recommendations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 20,
      "pageEnd": 21,
      "target": "../sections/sec-010-references.md",
      "narrative": null,
      "content": "1.\t UNAIDS data. Geneva: UNAIDS; 2020 (https://www.unaids.org/en/resources/\ndocuments/2020/unaids-data, accessed 4 February 2021).\n2.\t United Nations General Assembly. Political declaration on HIV and AIDS: intensifying our \nefforts to eliminate HIV and AIDS. New York: United Nations; 2011 (https://www.unaids.\norg/en/aboutunaids/unitednationsdeclarationsandgoals/2011highlevelmeetingonaids, \naccessed 4 February 2021).\n3.\t On the Fast-Track to an AIDS-free generation. Geneva: UNAIDS; 2016 (https://www.unaids.\norg/sites/default/files/media_asset/GlobalPlan2016_en.pdf, accessed 4 February 2021).\n4",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A reference list for the introduction, citing UNAIDS data, UN political declarations and earlier WHO HIV guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "CLINICAL GUIDELINES: ANTIRETROVIRAL DRUGS FOR HIV PREVENTION",
      "pageStart": 21,
      "pageEnd": 21,
      "target": "../sections/sec-011-2-clinical-guidelines-antiretroviral-drugs-for-h.md",
      "narrative": null,
      "content": "DRUGS FOR HIV PREVENTION",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section divider heading for the clinical guidelines on antiretroviral drugs for HIV prevention.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003The dapivirine vaginal ring",
      "pageStart": 21,
      "pageEnd": 22,
      "target": "../sections/sec-012-21-the-dapivirine-vaginal-ring.md",
      "narrative": null,
      "content": "Recommendation\nThe dapivirine vaginal ring may be offered as an additional prevention choice for women \nat substantial riska of HIV infection as part of combination prevention approaches.\n(conditional recommendation; moderate-certainty evidence)\na. \t \u0007Substantial risk of HIV infection is defined as HIV incidence greater than 3 per 100 person–years in the absence \nof PrEP (see Box 1).\nBackground\nPrEP (pre-exposure prophylaxis) is the use of ARV drugs by HIV-negative individuals to reduce \nthe acquisition of HIV infection. The results from randomized trials and subsequent open-\nlabel extension s",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the conditional recommendation that the dapivirine vaginal ring may be offered as an extra prevention choice for women at substantial HIV risk. It gives background on oral PrEP uptake since 2015 and describes the ring as a female-initiated silicone device releasing an NNRTI, and it notes that long-acting injectable cabotegravir was not yet assessed.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Box 1. \u0003Defining “substantial risk”",
      "pageStart": 22,
      "pageEnd": 30,
      "target": "../sections/sec-013-box-1-defining-substantial-risk.md",
      "narrative": null,
      "content": "Substantial risk of HIV infection is provisionally defined as HIV incidence greater than \n3 per 100 person-years in the absence of PrEP. HIV incidence greater than 3 per 100 \nperson-years has been identified among men who have sex with men, transgender \nwomen and heterosexual men and women who have sexual partners with undiagnosed \nor untreated HIV infection. Individual risk varies within groups at substantial risk \ndepending on individual behaviour and the characteristics of sexual partners. Most of \nthe PrEP trials reviewed for the 2015 WHO recommendation identified and recruited \ngroups at",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Defines substantial HIV risk as incidence above 3 per 100 person-years without PrEP and discusses how thresholds and risk assessment tools may vary. The section then covers evidence and considerations for the dapivirine vaginal ring, as the start and end of this cut block indicate. Its closing part discusses switching between or combining the ring and oral PrEP, the need for adherence, and unknowns about whether the ring adds new users or replaces oral PrEP. It ends with cost and cost-effectiveness, calling for further analysis using real-world data.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 30,
      "pageEnd": 34,
      "target": "../sections/sec-014-references.md",
      "narrative": null,
      "content": "1.\t Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O’Reilly KR, Koechlin FM et al. \nEffectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. \n2016;30:1973.\n2.\t Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for \nHIV. Geneva: World Health Organization; 2015 (https://www.who.int/hiv/pub/guidelines/\nearlyrelease-arv/en, accessed 4 February 2021).\n3.\t UNAIDS data. Geneva: UNAIDS; 2020 (https://www.unaids.org/en/resources/\ndocuments/2020/unaids-data, accessed 4 February 2021).\n4.\t Dapivirine Vaginal Ring 25 mg (dapivirine): An overv",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A reference list for the dapivirine vaginal ring section, citing PrEP trials, regulatory reviews and studies of ring use, acceptability and adherence among African women.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "CLINICAL GUIDELINES: DIAGNOSTICS AND TREATMENT MONITORING",
      "pageStart": 34,
      "pageEnd": 34,
      "target": "../sections/sec-015-3-clinical-guidelines-diagnostics-and-treatment.md",
      "narrative": null,
      "content": "TREATMENT MONITORING",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section divider heading for the clinical guidelines on diagnostics and treatment monitoring.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Point-of-care infant diagnosis",
      "pageStart": 34,
      "pageEnd": 40,
      "target": "../sections/sec-016-31-point-of-care-infant-diagnosis.md",
      "narrative": null,
      "content": "Recommendation\nPoint-of-care nucleic acid testing should be used to diagnose HIV among infants and \nchildren younger than 18 months of age.\n(strong recommendation; high-certainty evidence)\nBackground\nAlthough significant recent investments in improving the diagnostic networks, centralized \nlaboratories and sample collection networks have been made in most high-burden settings, \nclear improvements in access to infant testing and treatment initiation of infants have not \nincreased at the same rate. Substantial challenges and barriers remain. First, in 2019, only \n60% of infants received an HIV n",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the strong recommendation to use point-of-care nucleic acid testing to diagnose HIV in infants and children under 18 months. It explains the need, citing low early infant testing coverage, long laboratory turnaround times and high mortality among untreated infants. The later part of this cut block covers implementation, such as integrating point-of-care tools into laboratory networks, training and same-day linkage to care. It ends with research gaps, including quality assurance and a possible dual-use test for diagnosis and viral load.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Point-of-care viral load testing",
      "pageStart": 40,
      "pageEnd": 45,
      "target": "../sections/sec-017-32-point-of-care-viral-load-testing.md",
      "narrative": null,
      "content": "Recommendation\nPoint-of-care viral load may be used to monitor treatment among people living with HIV \nreceiving ART. \n(conditional recommendation; moderate-certainty evidence)\nBackground\nIn 2016, viral load testing was strongly recommended as the preferred approach to monitor \ntreatment among people living with HIV, with the associated development of a treatment \nmonitoring algorithm to identify potential adherence challenges or drug resistance – with \nthe latter requiring people to switch to a second-line treatment regimen (6). There has been \nsignificant uptake of viral load testing since 2",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the conditional recommendation that point-of-care viral load testing may be used to monitor people receiving ART. It describes the growth of viral load testing since 2016 and remaining barriers, and introduces new point-of-care technologies giving results within one to two hours. Implementation considerations include fitting the technology within the treatment monitoring algorithm, integrated laboratory networks and setting patient priorities given limited capacity. It notes that rapid results may help prevent drug resistance, especially in children and adolescents.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Box 2. \u0003Priorities for point-of-care viral load testing",
      "pageStart": 45,
      "pageEnd": 46,
      "target": "../sections/sec-018-box-2-priorities-for-point-of-care-viral-load-te.md",
      "narrative": null,
      "content": "Point-of-care viral load testing should be given priority for the following populations:\n•\tPregnant and breastfeeding women\n•\tInfants, children and adolescents\n•\tPeople requiring a repeat viral load after a first elevated viral load\n•\tPeople for whom treatment failure is suspected\n•\tPeople presenting sick, living with advanced HIV disease or having a known \nopportunistic infection (TB, cryptococcal infection, etc.)\n•\tFirst scheduled viral load test for people re-entering care\nFinally, priority should be given to ensuring adequate human resources, training (including \ntechnical, result interpre",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Box 2 lists priority groups for point-of-care viral load testing, such as pregnant and breastfeeding women, children and people with suspected treatment failure, and stresses training, quality assurance and treatment literacy. It ends with research gaps on optimizing implementation and a single test for diagnosis and viral load.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Treatment monitoring algorithm",
      "pageStart": 46,
      "pageEnd": 53,
      "target": "../sections/sec-019-33-treatment-monitoring-algorithm.md",
      "narrative": null,
      "content": "Background\nViral load testing was strongly recommended as the preferred approach to monitor treatment \namong people living with HIV in 2016, with the associated development of a treatment \nmonitoring algorithm to try to identify those who need to switch to second-line treatment if \ndrug resistance is suspected (6).\nSince the 2016 viral load algorithm was developed, ART programmes in low- and middle-\nincome countries have undergone changes that have altered the clinical ART context \nconsiderably. Two key programmatic shifts include rapid ART initiation (often on the same \nday as the diagnosis o",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the updated treatment monitoring algorithm in WHO's HIV guidance, noting that rapid ART initiation, the move from efavirenz-based regimens to dolutegravir and rising pretreatment NNRTI resistance have changed the context since the 2016 viral load algorithm. It reviews four questions: when to do the first viral load test, when to repeat it after an elevated result, whether to switch NNRTI-based regimens after a single test, and what threshold defines treatment failure. Supporting evidence is set out for each consideration. The section ends with research gaps, including the clinical relevance of low-level viraemia on dolutegravir and monitoring needs for children, adolescents and pregnant and breastfeeding women.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Diagnostic accuracy of alternative sample collection types (dried blood spot) or point of care with lower theoretical treatment failure thresholds",
      "pageStart": 50,
      "pageEnd": 50,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table shows the sensitivity (upper block) and specificity (lower block), with 95% confidence intervals, of dried blood spot and point-of-care viral load technologies from nine manufacturers for detecting treatment failure at thresholds from 1000 down to 200 copies/ml and at 'detectable'. Grey shading in the original marks values below 85%.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-340190/blocks/figure-vfig-p051",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 51,
      "pageEnd": 51,
      "target": "../figures/vfig-p051.webp",
      "narrative": "draft",
      "content": "Fig 1, a treatment monitoring algorithm for HIV. Routine viral load monitoring (results by 6 months and 12 months after ART initiation, then yearly) sorts results into undetectable (≤50 copies/ml), >50 to ≤1000 copies/ml, or >1000 copies/ml. Undetectable results mean maintaining the ARV drug regimen; higher results lead to enhanced adherence counselling and repeat viral load testing after 3 months, after which the regimen is maintained, maintained with continued counselling and retesting (>50 to ≤1000), or switched to an appropriate regimen (>1000). People on NNRTI-based regimens with >1000 copies/ml are switched to an appropriate regimen.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Box 3. \u0003Implementation considerations for treatment monitoring of pregnant and breastfeeding women",
      "pageStart": 53,
      "pageEnd": 54,
      "target": "../sections/sec-020-box-3-implementation-considerations-for-treatmen.md",
      "narrative": null,
      "content": "of pregnant and breastfeeding women\n•\tWhenever possible, use same-day point-of-care testing for viral load testing \nof pregnant and breastfeeding women to expedite the return of results and \nclinical decision-making. If this is not available, viral load specimens and results for \npregnant and breastfeeding women should be given priority across the laboratory \nreferral process (including specimen collection, testing and return of results).\n•\tAdherence counselling should be provided at all antenatal care and postnatal \nvisits to ensure that viral suppression is maintained throughout pregnancy an",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Box 3 sets out implementation considerations for viral load monitoring in pregnant and breastfeeding women, such as prioritizing same-day point-of-care testing and adherence counselling at every antenatal and postnatal visit. It specifies when to test according to the timing of ART initiation and what to do, including enhanced infant prophylaxis and infant testing, when viral load exceeds 1000 copies/ml.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 54,
      "pageEnd": 59,
      "target": "../sections/sec-021-references.md",
      "narrative": null,
      "content": "1.\t AIDSInfo [online database]. Geneva: UNAIDS; 2020 (http://aidsinfo.unaids.org, accessed \n4 February 2021).\n2.\t Bourne DE, Thompson M, Brody LL, Cotton M, Draper B, Laubscher R et al. Emergence of  \na peak in early infant mortality due to HIV/AIDS in South Africa. AIDS. 2009;23:101–6.\n3.\t Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA et al. Early antiretroviral \ntherapy and mortality among HIV-infected infants. N Engl J Med. 2008;359:2233–44.\n4.\t Markby J, Boeke C, Sacks J, Wang M, Peter T, Vojnov L. HIV early infant diagnosis testing \nprograms in low- and middle-income countr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of references for the chapters on infant diagnosis and treatment monitoring, citing mainly UNAIDS data, WHO guidelines and studies on point-of-care infant diagnosis and viral load testing, including dried blood spot samples.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "4. CLINICAL GUIDELINES: TIMING OF ANTIRETROVIRAL THERAPY",
      "pageStart": 59,
      "pageEnd": 59,
      "target": "../sections/sec-022-4-clinical-guidelines-timing-of-antiretroviral-t.md",
      "narrative": null,
      "content": "OF ANTIRETROVIRAL THERAPY",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for chapter 4 on clinical guidelines for the timing of antiretroviral therapy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Timing of ART for adults and children with TB",
      "pageStart": 59,
      "pageEnd": 61,
      "target": "../sections/sec-023-41-timing-of-art-for-adults-and-children-with-tb.md",
      "narrative": null,
      "content": "Recommendation\nART should be started as soon as possible within two weeks of initiating TB treatment, \nregardless of CD4 count, among people living with HIV.a\nAdults and adolescents \n(strong recommendation, low- to moderate-certainty evidence)\nChildren and infants \n(strong recommendation, very-low-certainty evidence)\na. \t Except when signs and symptoms of meningitis are present.\nBackground\nTB remains the leading cause of mortality among people living with HIV, despite substantial \nscale-up of ART, accounting for 30% of the AIDS-related deaths reported in 2019 (1). Since \n2010, WHO has recommen",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the recommendation that people living with HIV start ART as soon as possible within two weeks of starting TB treatment, whatever their CD4 count, except where meningitis is present. The background traces earlier WHO advice on ART timing during TB treatment and notes the lack of alignment with rapid ART guidance. Evidence summarized includes trials showing that immune reconstitution inflammatory syndrome was not more frequent with dolutegravir or raltegravir than with efavirenz.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Box 4. \u0003Importance of screening for signs and symptoms of meningitis",
      "pageStart": 61,
      "pageEnd": 65,
      "target": "../sections/sec-024-box-4-importance-of-screening-for-signs-and-symp.md",
      "narrative": null,
      "content": "meningitis\nAmong people living with HIV with TB meningitis or other forms of meningeal infection \nsuch as cryptococcus, earlier ART is associated with more severe adverse events and \nincreased mortality with cryptococcal meningitis. For people living with HIV with TB \nmeningitis, immediate ART is associated with more severe adverse events compared \nwith initiating ART two months after the start of TB treatment.a\n•\tART should be delayed by 4–6 weeks of ART following initiation of treatment for \ncryptococcal meningitis. Use of steroids is not recommended.a\n•\tART should be delayed at least four w",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Box 4 explains that ART should be delayed in people with cryptococcal or TB meningitis, for 4–6 weeks and at least four weeks respectively, because early treatment raises adverse events and mortality. The section then extends the earlier-ART recommendation to children by extrapolation from adult evidence, given the high risks of delay in young children. It closes with research gaps on newer ARVs in TB coinfection, corticosteroids to prevent immune reconstitution syndrome and multi-disease adherence support.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 65,
      "pageEnd": 67,
      "target": "../sections/sec-025-references.md",
      "narrative": null,
      "content": "1.\t Global tuberculosis report. Geneva: World Health Organization; 2020 (https://www.who.\nint/publications/i/item/9789240013131, accessed 4 February 2021).\n2.\t Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV \ninfection: recommendations for a public health approach – second edition. Geneva: World \nHealth Organization; 2016 (https://www.who.int/hiv/pub/arv/arv-2016/en, accessed 4 \nFebruary 2021).\n3.\t Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. \nGeneva: World Health Organization; 2017 (https://www.who.int/",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of references for the section on ART timing in people with TB, citing WHO TB and HIV guidelines and trials of early versus delayed ART during TB treatment.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "\u0003Updated clinical considerations for rapid ART initiation",
      "pageStart": 67,
      "pageEnd": 67,
      "target": "../sections/sec-026-42-updated-clinical-considerations-for-rapid-art.md",
      "narrative": null,
      "content": "A systematic review was conducted to address the applicability of a minimum set of TB \nexclusion criteria (signs and symptoms) to enable same-day ART initiation among people newly \ndiagnosed with HIV. The review (see Web Annexes) (1) identified four studies that met the \ninclusion criteria, but none directly addressed the question. However, the review findings did \nindicate that same-day ART initiation for people with symptoms suggesting TB was feasible. \nAfter examining the above evidence, the Guideline Development Group agreed that, rather \nthan pursue a new recommendation, WHO would further",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Reports that a systematic review on TB symptom criteria for same-day ART initiation found no studies directly addressing the question, so the Guideline Development Group chose to clarify clinical considerations rather than make a new recommendation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Box 5. \u0003Clinical considerations for people living with HIV being evaluated for rapid ART initiation",
      "pageStart": 67,
      "pageEnd": 70,
      "target": "../sections/sec-027-box-5-clinical-considerations-for-people-living.md",
      "narrative": null,
      "content": "evaluated for rapid ART initiation\nThe Guideline Development Group suggested the following update to existing guidance \non rapid ART initiation (2): \n•\tprevious clinical consideration: brief delay in ART initiation while investigating for \nTB symptoms; and\n•\tnew clinical consideration: among people living with HIV with signs and symptoms \nsuggesting TB, except for central nervous system disease (meningitis), initiate ART \nwhile rapidly investigating for TB, with close follow-up within seven days to initiate \nTB treatment if TB is confirmed.\nCaution is needed for people living with HIV who have",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Box 5 revises rapid ART guidance so that people with signs of TB, other than meningitis, start ART while TB is rapidly investigated, with follow-up within seven days, whereas ART is delayed if TB or cryptococcal meningitis is suspected. The background notes that TB caused 30% of HIV-associated deaths in 2019 and that rapid ART initiation has been recommended since 2017. Research gaps include the effect of this approach on care outcomes and the role of prophylactic corticosteroids in preventing immune reconstitution syndrome.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 70,
      "pageEnd": 72,
      "target": "../sections/sec-028-references.md",
      "narrative": null,
      "content": "1.\t Burke R, Macpherson P, Rickman H, Singh S, Hosseinipour M, Wilkinson RJ et al. What \ntuberculosis symptoms preclude safe same-day ART initiation? [Abstract available in \nWeb Annex C.1] \n2.\t Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. \nGeneva: World Health Organization; 2017 (https://www.who.int/hiv/pub/guidelines/\nadvanced-HIV-disease/en, accessed 4 February 2021).\n3.\t Global tuberculosis report. Geneva: World Health Organization; 2020 (https://www.who.\nint/publications/i/item/9789240013131, accessed 4 February 2021).\n4.\t Guidelines for mana",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A reference list for the rapid ART section, followed by short sections on how WHO will monitor uptake of the guidelines, potential barriers, and modular updating of the guidance.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "DISSEMINATING, ADAPTING AND IMPLEMENTING THE GUIDELINES",
      "pageStart": 72,
      "pageEnd": 73,
      "target": "../sections/sec-029-5-disseminating-adapting-and-implementing-the-gu.md",
      "narrative": null,
      "content": "IMPLEMENTING THE GUIDELINES\n11 Weblinks: www.hivtx.org/iphone, www.hivtx.org/android",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A section heading for disseminating, adapting and implementing the guidelines, with web links to a mobile app.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annexes",
      "pageStart": 73,
      "pageEnd": 73,
      "target": "../sections/sec-030-annexes.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 1. Process for developing the clinical guideline",
      "pageStart": 73,
      "pageEnd": 76,
      "target": "../sections/sec-031-annex-1-process-for-developing-the-clinical-guid.md",
      "narrative": null,
      "content": "Background\nThe WHO 2013 consolidated guidelines for antiretroviral therapy combined recommendations \nacross the continuum of HIV care for the first time. This was updated in 2016. Since then, \ngrowing evidence in clinical and operational studies necessitated developing updated \nnormative guidance. Several supplementary guidelines have been published with a modular \napproach to address the emerging evidence. Table A1 summarizes key normative guidance \nreleased since 2016 up to the time this document was written, mapped to the relevant chapters \nof the 2016 consolidated guidelines. The recommend",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 1 describes the background to developing this clinical guideline, explaining that it updates the 2016 consolidated ARV guidelines in a modular way. Table A1 maps guidance issued since 2016 to the chapters of the consolidated guidelines, and a figure shows the hub-and-spoke model of technical scoping meetings. It notes the new recommendations will be integrated into the 2021 consolidated guidelines.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A1. Summary of key normative guidance released and ongoing since 2016, mapped to the corresponding chapters of the consolidated guidelines",
      "pageStart": 73,
      "pageEnd": 74,
      "target": "../tables/table-a1.csv",
      "narrative": "draft",
      "content": "The table maps key WHO normative guidance on HIV released since 2016 to the chapters of the consolidated guidelines on antiretroviral drugs, from HIV diagnosis to cross-cutting guidelines. For each chapter it lists the key guidance published between 2016 and 2020 with dates, and the latest or upcoming guidance.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Table A2. Technical scoping meetings to inform the clinical guideline update",
      "pageStart": 76,
      "pageEnd": 77,
      "target": "../sections/sec-032-table-a2-technical-scoping-meetings-to-inform-th.md",
      "narrative": null,
      "content": "guideline update\nDetails of scoping meetings held\nDate\nHIV and TB scoping consultation\n2019\nHIV treatment transition and drug sequencing in the context of new antiretroviral \ndrugs (at the Conference on Retroviruses and Opportunistic Infections): think tank\nhttps://www.who.int/hiv/pub/meetingreports/think-tank-HIVtreatment-croi2017/en\n2017\nPartners synergy meeting\n2017\nWHO Meeting on Treatment and Monitoring Optimization of HIV (at the \nConference on Retroviruses and Opportunistic Infections)\nhttps://www.who.int/hiv/pub/meetingreports/arv-optimization-2018/en\n2018\nTechnical consultation on inf",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Table A2 lists technical scoping meetings held between 2017 and 2020 that informed the guideline update, and the text describes the virtual Guideline Development Group meeting held in late 2020 because of COVID-19. It explains how seven systematic reviews and other evidence were summarized and rated using GRADE.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A2. Technical scoping meetings to inform the clinical guideline update",
      "pageStart": 76,
      "pageEnd": 76,
      "target": "../tables/table-a2.csv",
      "narrative": "draft",
      "content": "The table lists the technical scoping meetings held to inform the clinical guideline update, with links to meeting reports where available, and the year each meeting took place.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Table A3. Summary of PICO questions",
      "pageStart": 77,
      "pageEnd": 80,
      "target": "../sections/sec-033-table-a3-summary-of-pico-questions.md",
      "narrative": null,
      "content": "PICO question\nSummary of systematic review methods\nPICO 1: Should the dapivirine \nvaginal ring be offered as an \nadditional prevention choice for \nwomen at substantial risk of HIV \ninfection as part of combination \nprevention approaches?\nReview type: Systematic review and meta-analysis\nReview lead: Medical University of South Carolina, USA\nSearch dates: 1 January 2010 to 3 August 2020\nDatabases searched: PubMed, CINAHL (Cumulative Index to Nursing \nand Allied Health Literature) and EMBASE\nNumber of studies and study design: Five studies were included, \ncomprising data from 10 articles and 8 co",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Table A3 summarizes the methods of the systematic reviews behind each PICO question, including the dapivirine vaginal ring, point-of-care infant diagnosis and point-of-care viral load monitoring, with review leads, search dates and included studies. The text then describes how the virtual meeting was run, with a 60% voting threshold agreed but all recommendations reached by consensus. Evidence-to-decision tables were prepared in line with GRADE and discussed with a methodologist.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A3. Summary of PICO questions",
      "pageStart": 77,
      "pageEnd": 78,
      "target": "../tables/table-a3.csv",
      "narrative": "draft",
      "content": "The table lists the six PICO questions addressed by the guideline update, and for each summarizes the systematic review methods: review type, review lead or team, search dates, databases searched, and the number and design of included studies.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Table A4. Criteria for consideration in evidence-to-decision-making tables",
      "pageStart": 80,
      "pageEnd": 82,
      "target": "../sections/sec-034-table-a4-criteria-for-consideration-in-evidence.md",
      "narrative": null,
      "content": "making tables\nDomain\nRationale\nCertainty of the evidence\nThis is an assessment of the degree of confidence in the estimate of the \neffect: that is, the likelihood that the effect will differ substantially from what \nthe research found. “Differ substantially” means a large enough difference \nthat it might affect a decision.\nBenefits and risks\nWhen a new recommendation is developed, desirable effects (benefits) \nneed to be weighed against the undesirable effects (risks), considering \nany previous recommendation or another alternative. The larger the gap or \ngradient in favour of the benefits ove",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Table A4 defines the criteria used in evidence-to-decision tables, such as certainty of evidence, benefits and risks, values, costs, equity and acceptability. The text then describes how conflicts of interest of the External Review Group were managed and how the draft guidelines were peer reviewed in November 2020.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/table-005",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table A4. Criteria for consideration in evidence-to-decision-making tables",
      "pageStart": 80,
      "pageEnd": 80,
      "target": "../tables/table-a4.csv",
      "narrative": "draft",
      "content": "The table lists the domains considered in the evidence-to-decision-making tables (certainty of the evidence, benefits and risks, values of outcomes, cost and resource implications, equity, acceptability and feasibility) and gives the rationale for each.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-340190/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Annex 2. Simplified infant diagnosis algorithm",
      "pageStart": 82,
      "pageEnd": 84,
      "target": "../sections/sec-035-annex-2-simplified-infant-diagnosis-algorithm.md",
      "narrative": null,
      "content": "The key principles for establishing whether HIV-\nexposed infants and children younger than 18 \nmonths are infected with HIV in low- and middle-\nincome countries are as follows.\n•\t Assess HIV exposure status by antibody testing \nthe mother.\n•\t Perform nucleic-acid testing for any HIV-\nexposed child who presents outside the national \ninfant testing algorithm with clinical symptoms, \nregardless of previous nucleic-acid test results\n•\t At nine months, perform nucleic-acid testing \nfor HIV-exposed infants, symptomatic and \nasymptomatic, and even if previous nucleic-acid \ntest results have been nega",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Annex 2 presents a simplified algorithm for diagnosing HIV in exposed infants and children under 18 months, with key principles such as testing the mother, NAT at nine months and confirming any positive result. Notes explain birth testing, point-of-care NAT and retesting to avoid false positives, and the page ends with WHO HIV department contact details.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-340190/blocks/figure-img-p084-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 84,
      "pageEnd": 84,
      "target": "../images/img-p084-1.webp",
      "narrative": "draft",
      "content": "ISBN barcode for 9789240022232.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
